A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting

Immune checkpoint inhibitors (ICIs) are changing all aspects of malignant tumour therapy as an immunotherapy subverter in oncology. However, the current ICIs might induce systemic immune activation in other tissues and organs since they are not tumour-specific, causing the immune system to attack so...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ying, Song, Shuyi, Yuan, Baomei, Wu, Yahong, Gao, Yanfeng, Wan, Guangming, Li, Guodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532478/
https://www.ncbi.nlm.nih.gov/pubmed/36195696
http://dx.doi.org/10.1007/s12672-022-00562-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532478/
https://www.ncbi.nlm.nih.gov/pubmed/36195696
http://dx.doi.org/10.1007/s12672-022-00562-6

Ejemplares similares